Seeking Alpha

Shares of Exelixis (EXEL) gain 20% premarket after the firm announces positive top-line results...

Shares of Exelixis (EXEL) gain 20% premarket after the firm announces positive top-line results from its Phase 3 clinical trail of cabozantinib in patients with medullary thyroid cancer. The company aims to build a cabozantinib franchise that includes large indications such as prostate cancer.
From other sites
Comments (1)
  • TruffelPig
    , contributor
    Comments (4108) | Send Message
     
    This is a real winner. That stuff also seems to work against bone metastasis! Looks like multi billion dollar potential. Also, EXEL was trading with a 50% discount until this morning - still time to jump in I think. I am just too happy about the puts I sold :).

     

    Long EXEL :) (stocks and puts sold)
    24 Oct 2011, 09:24 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs